#135105
Re: Farmas USA
AMRN en velas trimestrales
hay alguna razón para pensar que 2024 sera bueno para este stock??
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Dear Biotech Investor,
Biotech is back with multiple premium buyouts in the last few weeks; Prometheus was bought by Merck for $11 billion, a 75% premium, in a bidding war with other Big Pharmas. Merck lost out to Pfizer who just bought SGEN for $40 billion for their expertise in new cancer drugs, specifically ADCs like Padcev which are targeted monoclonal antibodies with killing agents attached.
With interest rates peaking/about to peak, the biotech sector is poised to move higher. Big Pharma knows this and is buying biotech before the big move. We currently have a recommendation that makes 2nd generation ADCs and in fact has a better and safer Padcev in development, one of the key ADCs Merck acquired from SGEN. We also have a new recommendation in the hottest sector in drug development; obesity/type 2 diabetes that we would love to share with you.
Subscribe today to access both of these cutting edge biotech recommendations.
- John McCamant, Editor